Beyond seropositivity: quantitative parietal cell antibody titers predict gastric intestinal metaplasia in a high helicobacter pylori prevalence setting
- 14 October 2026
- journal article
- research article
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- p. 1-9
Abstract
Purpose Anti-gastric parietal cell antibody (APA) positivity is a recognized serological biomarker for autoimmune gastritis, but whether quantitative APA titer levels correlate with the severity of gastric intestinal metaplasia (GIM) in high Helicobacter pylori (H. pylori) prevalence settings remains unclear. This study aimed to evaluate the association between quantitative APA titer dilutions and histopathological GIM in a large endoscopic cohort. Methods In this retrospective cohort study, medical records of adult patients who underwent APA testing at a tertiary referral center between November 2017 and November 2019 were reviewed. Of 1,104 screened patients, 453 met inclusion criteria after excluding those with repeated testing or missing data; following exclusion of 118 patients without gastroscopy or adequate biopsy sampling, 335 patients who underwent standardized topographical gastric biopsy mapping constituted the definitive analysis cohort. Associations between APA status/titer dilutions and histopathological findings were assessed using chi-squared tests and multivariate logistic regression. Results GIM was present in 24.5% (n = 82) of the cohort. APA positivity was significantly associated with GIM (40.5% vs. 15.4% in APA-negative patients, p 1:320 dilution subgroups. In multivariate analysis, each incremental step-up in APA titer dilution (OR 1.522, 95% CI 1.304-1.776) and advancing age (OR 1.043, 95% CI 1.021-1.066) independently predicted GIM, while active H. pylori infection was an independent negative predictor (OR 0.348, 95% CI 0.184-0.660). Conclusion Quantitative APA titers, rather than binary positivity, demonstrate a clear dose-response relationship with histopathological GIM. Titers of 1:320 or greater identify a clinically actionable threshold that may guide prioritization of endoscopic evaluation with standardized topographical biopsy mapping.Keywords
This publication has 14 references indexed in Scilit:
- Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025Endoscopy, 2025
- Long-Term Natural History of Autoimmune Gastritis: Results From a Prospective Monocentric SeriesAmerican Journal of Gastroenterology, 2023
- Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori -negative patientsGut, 2022
- Analysis of clinical characteristics of 2243 with positive anti‐gastric parietal cell antibodyJournal of Clinical Laboratory Analysis, 2020
- Natural history of autoimmune atrophic gastritis: a prospective, single centre, long‐term experienceAlimentary Pharmacology & Therapeutics, 2019
- Pathophysiology of Gastric NETs: Role of Gastrin and MeninCurrent Gastroenterology Reports, 2017
- Anti-parietal cell antibodies – diagnostic significanceAdvances in Medical Sciences, 2016
- Autoimmune atrophic gastritis—pathogenesis, pathology and managementNature Reviews Gastroenterology & Hepatology, 2013
- Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletionBlood, 2006
- Helicobacter pylori Adhesin Binding Fucosylated Histo-Blood Group Antigens Revealed by RetaggingScience, 1998